<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32823450</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1998-3689</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Indian journal of ophthalmology</Title>
          <ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Commentary: Rituximab in scleritis.</ArticleTitle>
        <Pagination>
          <StartPage>1983</StartPage>
          <EndPage>1985</EndPage>
          <MedlinePgn>1983-1985</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4103/ijo.IJO_896_20</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dutta Majumder</LastName>
            <ForeName>Parthopratim</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Uvea, Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, Tamil Nadu, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Indian J Ophthalmol</MedlineTA>
        <NlmUniqueID>0405376</NlmUniqueID>
        <ISSNLinking>0301-4738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
          <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Indian J Ophthalmol. 2020 Sep;68(9):1981-1983</RefSource>
          <PMID Version="1">32823449</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014890" MajorTopicYN="Y">Granulomatosis with Polyangiitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015423" MajorTopicYN="Y">Scleritis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>None</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32823450</ArticleId>
        <ArticleId IdType="pmc">PMC7690482</ArticleId>
        <ArticleId IdType="doi">10.4103/ijo.IJO_896_20</ArticleId>
        <ArticleId IdType="pii">IndianJOphthalmol_2020_68_9_1983_292595</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. SurvOphthalmol. 2005;50:351–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15967190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murthy SI, Shah S, Bagga B, Dudam R. Rituximab therapy combined with methotrexate for severe necrotizing scleritis in a case of granulomatosis with polyangiitis. Indian J Ophthalmol. 2020;68:1981–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7690469</ArticleId>
            <ArticleId IdType="pubmed">32823449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritisand uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61:44–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29635229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm. 2008;16:230–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19065418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al.  Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalizeddisease. Ophthalmology. 2015;122:1262–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25745876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, Lee ST, et al.  Rituximab therapy for refractory scleritis: Results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121:1885–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24953794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauhan S, Kamal A, Thompson RN, Estrach C, Moots RJ. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol. 2009;93:984–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19553514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasi SK, Kim HJ, Basham RP, Cunningham ET, Sy A, Lustig L, et al.  Idiopathic orbital inflammation associated with necrotizing scleritisand temporal bone inflammation. Ophthal Plast Reconstr Surg. 2016;32:e77–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25126771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1755562</ArticleId>
            <ArticleId IdType="pubmed">15958765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao JH, Oray M, Cocho L, Foster CS. Rituximab in the treatment of refractory noninfectiousscleritis. Am J Ophthalmol. 2016;164:22–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26766304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stilling-Vinther MK, Pedersen BS. Fatal pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol (Copenh) 2012;90:e154–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21649871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bussone G, Kaswin G, de Menthon M, Delair E, Brézin AP, Guillevin L. Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis. Clin Exp Rheumatol. 2010;28(1 Suppl 57):90–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20412711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>You C, Ma L, Lasave AF, Foster CS. Rituximab induction and maintenance treatment in patients with scleritisand granulomatosis with polyangiitis (Wegener's) Ocul Immunol Inflamm. 2018;26:1166–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28628344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recillas-Gispert C, Serna-Ojeda JC, Flores-Suárez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's) Graefes Arch Clin Exp Ophthalmol. 2015;253:2279–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26507398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor SRJ, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009;60:1540–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19404964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-JacoisteAsín MA, Charles P, Rothschild PR, Terrier B, Brézin A, Mouthon L, et al.  Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. Autoimmun Rev. 2019;18:493–500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30844550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardy S, Hashemi K, Catanese M, Candil M, Zufferey P, Gabison E, et al.  Necrotising scleritisand peripheral ulcerative keratitis Associated with rheumatoid arthritis treated with rituximab. Klin Monatsbl Augenheilkd. 2017;234:567–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28147401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurz PA, Suhler EB, Choi D, Rosenbaum JT. Rituximab for treatment of ocular inflammatory disease: A series of four cases. Br J Ophthalmol. 2009;93:546–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19321476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdanic-Werner K, Fernandez-Sanz G, Alejandre Alba N, Ferrer Soldevila P, Romero-Bueno FI, Sanchez-Pernaute O. Rituximab therapy for refractory idiopathic scleritis. Ocul Immunol Inflamm. 2013;21:329–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23662782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita Y, Fukui S, Endo Y, Tsuji S, Takatani A, Shimizu T, et al.  Peripheral ulcerative keratitis associated with granulomatosis with polyangiitisemerging despite cyclophosphamide, successfully treated with rituximab. Intern Med Tokyo Jpn. 2018;57:1783–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6047997</ArticleId>
            <ArticleId IdType="pubmed">29321417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C, Ricciuti A, Caturegli P, Keene CD, Kargi AY. Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab. Pituitary. 2015;18:441–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25224140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caso F, Fiocco U, Costa L, Sfriso P, Punzi L, Doria A. Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine. 2014;81:190–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23932926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FidelixTS de A, Vieira LA, Trevisani VF. Management of necrotizing scleritis after pterygium surgery with rituximab. Arq Bras Oftalmol. 2016;79:339–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27982218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung CM, Murray PI, Savage COS. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1772907</ArticleId>
            <ArticleId IdType="pubmed">16234479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morarji J, Joshi L, Tomkins-Netzer O, Lightman S, Taylor SR. Combined infliximab and rituximab in necrotising scleritis. Case Rep Ophthalmol. 2012;3:286–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3530152</ArticleId>
            <ArticleId IdType="pubmed">23275790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. OculImmunolInflamm. 2010;18:223–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20482403</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
